Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Calithera Biosciences Inc

Financial Services US CALA

0.0003USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

0.00010.005
LowHigh

Fundamentals

  • Previous Close 0.0003
  • Market Cap0.00049M
  • Volume315
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-41.81900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -28.53300M
  • Diluted EPS TTM-1.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -39.65000M -115.08800M -90.13700M -89.86000M -54.62900M
Minority interest - - - - -
Net income -18.86600M -165.33800M -88.52300M -86.34600M -51.47200M
Selling general administrative 13.54M 20.85M 20.37M 16.61M 13.34M
Selling and marketing expenses - - - - -
Gross profit - 9.75M - -76.29000M 22.25M
Reconciled depreciation 0.26M 0.28M 0.36M 0.48M 0.51M
Ebit -42.07400M -115.43300M -91.75100M -93.37400M -57.78600M
Ebitda -43.76600M -13.68300M -91.38700M -92.89500M -57.28100M
Depreciation and amortization -1.69200M 101.75M 0.36M 0.48M 0.51M
Non operating income net other - - 1.25M 3.04M -
Operating income -42.07400M -115.43300M -91.38700M -92.89500M -57.28100M
Other operating expenses 42.07M 74.31M 91.39M 92.89M 79.53M
Interest expense -20.78400M 0.34M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.48M 0.34M 1.25M 3.04M 2.65M
Net interest income 0.48M 0.34M 1.25M 3.04M 2.65M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -20.78400M 50.25M -1.61400M -3.51400M -3.15700M
Total revenue 0.00000M 9.75M 0.00000M 0.00000M 22.25M
Total operating expenses 42.07M 74.31M 91.39M 92.89M 79.53M
Cost of revenue - - - 76.29M 66.19M
Total other income expense net 2.42M 0.34M 1.25M 3.04M 2.65M
Discontinued operations - - - - -
Net income from continuing ops -39.65000M -115.08800M -90.13700M -89.86000M -54.62900M
Net income applicable to common shares - -115.08800M -90.13700M -89.86000M -54.62900M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 28.68M 64.76M 125.59M 168.77M 142.72M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.17M 1.92M 3.55M 2.44M 4.10M
Total liab 8.28M 56.37M 23.22M 26.34M 16.01M
Total stockholder equity 20.39M -491.32600M -376.23800M -286.10100M -196.17000M
Deferred long term liab - - - - 1.13M
Other current liab 5.13M 0.61M 1.45M 14.55M 11.17M
Common stock - 0.00800M 0.00700M 0.00600M 0.00400M
Capital stock 22.34M 0.00800M 0.00700M 0.00600M 0.00400M
Retained earnings -512.61600M -491.32600M -376.23800M -286.10100M -196.17000M
Other liab - - - - 1.13M
Good will - - - - -
Other assets - 0.27M 6.19M 0.72M 1.01M
Cash 25.45M 59.54M 107.15M 60.44M 51.06M
Cash and equivalents - - - - -
Total current liabilities 7.39M 14.01M 18.40M 19.62M 14.88M
Current deferred revenue - 8.37M 13.05M 1.55M 2.47M
Net debt -23.78500M -56.49700M -100.42800M -52.24100M -51.05800M
Short term debt 1.53M 1.37M 1.90M 1.48M -
Short long term debt - - - - -
Short long term debt total 1.67M 3.04M 6.72M 8.20M -
Other stockholder equity 510.67M -0.00800M -0.01000M -0.04800M 0.11M
Property plant equipment - 3.03M 6.44M 0.99M 1.46M
Total current assets 26.62M 61.45M 118.70M 159.80M 140.25M
Long term investments - - - - 0.00000M
Net tangible assets - 8.38M 102.37M 142.43M 126.71M
Short term investments - 0.00000M 8.01M 96.92M 85.09M
Net receivables - 0.00000M 1.54M 0.48M 2.00M
Long term debt - - - - -
Inventory - - -1.54100M -0.48200M -1.99700M
Accounts payable 0.73M 3.65M 1.99M 2.05M 1.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -40.70200M 0.00300M 0.04M -0.11300M
Additional paid in capital - - - - -
Common stock total equity - - 0.00700M 0.00600M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - - -376.23800M -286.10100M -196.17000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.27M 0.27M 0.44M 0.72M 1.01M
Deferred long term asset charges - - - - -
Non current assets total 2.05M 3.30M 6.88M 8.97M 2.47M
Capital lease obligations 1.67M 3.04M 6.72M 8.20M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.13300M 7.85M 88.96M -10.77700M 53.01M
Change to liabilities - 1.66M -0.05800M 3.39M 4.90M
Total cashflows from investing activities - 7.85M 88.96M -10.78400M 52.80M
Net borrowings - - - - -
Total cash from financing activities 9.65M 10.67M 42.06M 98.91M 14.63M
Change to operating activities - -6.60200M -2.84600M 1.37M 5.05M
Net income -39.65000M -115.08800M -90.13700M -89.86000M -54.62900M
Change in cash -34.08600M -47.77900M 46.71M 9.38M 2.58M
Begin period cash flow 59.81M 107.59M 60.88M 51.50M 48.91M
End period cash flow 25.72M 59.81M 107.59M 60.88M 51.50M
Total cash from operating activities -43.60800M -66.30000M -84.31200M -78.74500M -64.84200M
Issuance of capital stock 9.64M 10.66M 40.86M 97.69M 13.71M
Depreciation 0.26M 0.28M 0.36M 0.48M 0.51M
Other cashflows from investing activities - - - -10.77700M 53.01M
Dividends paid - - - - -
Change to inventory - - - 1.08M 5.01M
Change to account receivables - 1.54M -1.05900M 1.51M -0.85500M
Sale purchase of stock - - 8.60M 45.15M 14.63M
Other cashflows from financing activities 0.02M 0.00400M 1.20M 1.22M 0.92M
Change to netincome - 51.91M 9.42M 5.00M 7.44M
Capital expenditures 0.13M 0.15M 0.06M 0.00700M 0.21M
Change receivables - - -1.05900M 1.51M -0.85500M
Cash flows other operating - - 1.73M 1.63M -21.92800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 46.71M 9.38M 2.58M
Change in working capital -7.42600M -3.40500M -3.96300M 3.70M -17.88300M
Stock based compensation 4.03M 10.26M 8.06M 6.47M 7.44M
Other non cash items -0.81700M 41.65M 1.51M 1.37M -0.27200M
Free cash flow -43.74100M -66.44700M -84.37300M -78.75200M -65.05600M

Peer Comparison

Sector: Financial Services Industry: Shell Companies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CALA
Calithera Biosciences Inc		 - -% 0.0003 - - 1.71 0.07 0.01 0.18
CLUS
CLUS		 - -% 200.00 - - 0.09 0.92 0.72 -8.9658
SVMB
SavMobi Technology Inc.		 - -% 1.00 - - 239.23 - 363.28 -319.6012
PBAJ
Petro Usa Inc		 - -% 0.0005 - - - - -9042.9978
ALSAF
ALSAF		 - -% 15.40 - - - 0.85

Reports Covered

Stock Research & News

View All

Profile

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Calithera Biosciences Inc

343 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Susan M. Molineaux Ph.D. Founder, CEO, Pres & Director 1954
Ms. Stephanie Wong CFO & Sec. 1974
Dr. Eric B. Sjogren Sr. VP of Drug Discovery 1957
Dr. Christopher J. Molineaux Ph.D. Sr. VP of Devel. 1953
Mr. Frank Parlati Ph.D. Sr. VP of Research 1969
Dr. Emil T. Kuriakose M.D. Chief Medical Officer 1980
Dr. Susan B. Demo Ph.D. Sr. VP of R&D Operations NA
Dr. Allison Dillon Ph.D. Sr. VP of Commercial & Portfolio Strategy NA
Ms. Stephanie Wong CPA CFO & Secretary 1974
Dr. Christopher J. Molineaux Ph.D. Senior Vice President of Development 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.